Journal article
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis
Abstract
Lysophosphatidic acid (LPA)-mediated activation of LPA receptor 1 (LPAR1) contributes to the pathophysiology of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc). These diseases are associated with high morbidity and mortality despite current treatment options. The LPA-producing enzyme autotaxin (ATX) and LPAR1 activation contribute to inflammation and mechanisms underlying fibrosis in preclinical …
Authors
Volkmann ER; Denton CP; Kolb M; Wijsenbeek-Lourens MS; Emson C; Hudson K; Amatucci AJ; Distler O; Allanore Y; Khanna D
Journal
European Respiratory Review, Vol. 33, No. 172,
Publisher
European Respiratory Society (ERS)
Publication Date
April 30, 2024
DOI
10.1183/16000617.0015-2024
ISSN
0905-9180